

Examiner Initial	Document No.	Document
	6	International Preliminary Examination Report, issued February 9, 2004, in connection with International Patent Application No. PCT/US02/21768
	7	Office Action, issued February 7, 1995, in connection with U.S. Patent Application Serial No. 08/285,984
	8	Office Action, issued December 27, 2006, in connection with U.S. Patent Application Serial No. 10/762,226
	9	Office Action, issued March 29, 2005, in connection with U.S. Patent Application Serial No. 10/104,607
	10	Office Action, issued September 21, 2005, in connection with U.S. Patent Application Serial No. 10/192,257
	11	WO 04/023148
	12	"Clinical trial initiated with chemorefractory patients," Cancer Weekly, The Gale Group, (2001)
	13	"Clinical trials update," Scrip, Informa UK Ltd., 2547:25, (2000)
	14	"Gastrin 17 immunogen Aphton begins combination study," R & D Focus Drug News, IMS World Publications, (2000)
	15	"Other news to note," Bioworld Today, American Health Consultants Inc., 11(82), (2000)
	16	Abdalla et al., "Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis" Clin. Cancer Res. 10:4784-4792 (2004)
	17	Aphton Biopharma BIO2005 Presentation, June 19-22, Philadelphia, PA (2005), 26 pages
	18	Ardis R&D Profile, "Gastrin 17 vaccine--Aphton: Anti-gastrin 17 immunogen, G17DT," Biodrugs 17(3):223-225 (2003)
	19	Caplin et al., "Expression and processing of gastrin in pancreatic adenocarcinoma" Brit. J. Surgery 87:1035-1040 (2000).
	20	Caplin et al., "Demonstration of new sites of expression of the CCK-B/gastrin receptor in pancreatic acinar AR42J cells using immunoelectron microscopy," Regulatory Peptides, 84(1-3):81-89, (1999)
	21	Caplin et al., "Effect of gastrin and anti-gastrin antibodies on proliferation of hepatocyte cell lines," Digestive Diseases and Sciences, 46(7):1356-1366, (2001)
	22	Chaudhry et al., "Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer" Clin. Cancer Res. 5:3385-3393 (1999)
	23	Dufresne et al., "Cholecystikinin and Gastrin Receptors", Physiol Rev. 86:805-847 (2006)
	24	Gilliam et al., "A Phase II study of G17DT in gastric carcinoma" EJSO 30:536-543 (2004)

Examiner Initial	Document No.	Document
	25	Gilliam et al., "G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy" Expert Opin Biol Ther. 7(3):397-404 (2007)
	26	Gilliam et al., "Randomised, double blind, placebo-controlled, multi-centre, group-sequential trial of G17DT for patients with advanced pancreatic cancer unsuitable or unwilling to take chemotherapy" J. Clin. Oncol. ASCO Annual Meeting Proceedings 22(14S):2511 (2004)
	27	Gocyk, W., et al., "Helicobacter pylori, gastrin and cyclooxygenase-2 in lung cancer," Medical Science Monitor, 6(6):1085-1092 (2000)
	28	Haigh et al. "Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor" Gastroenterology 124: 615-625 (2003)
	29	Harris et al., "An antiapoptotic role for gastrin and the gastrin/CCK-2 receptor in Barrett's esophagus," Cancer Res. 64(6):1915-1919 (2004)
	30	Harris et al., "The biological and therapeutic importance of gastrin gene expression in pancreatic adenocarcinomas", Cancer Res. 64:5624-5631 (2004)
	31	Kaiser, "First pass at cancer genome reveals complex landscape" Science 313, 1370 (2006)
	32	Koh et al., "Glycine-Extended Gastrin Promotes the Growth of Lung Cancer" Cancer Res. 64:196-201 (2004)
	33	McWilliams et al., "Antibodies raised against the extracellular tail of the CCKB/gastrin receptor inhibit gastrin-stimulated signaling," Regulatory Peptides, 99(2-3):157-161, (2001)
	34	MSNBC News Services, "Mixed results on new cancer drug," November 9, 2000 (4 pages)
	35	Pannequin et al., "Divergent roles for ferric ions in the biological activity of amidated and non-amidated gastrins" J. Endocrinol. 181(2):315-325 (2004)
	36	Schmitz et al., "CCK-B/gastrin receptors in human colorectal cancer" European J. Clinical Investigation 31:812-820 (2001)
	37	Senior, "Immunization blocks gastrin's ability to promote tumour cell division" Drug Disc. Today 6(2):62-63 (2001)
	38	Smith, A.M. and S.A. Watson, "Review article: gastrin and colorectal cancer," Alimentary Pharmacology & Therapeutics, 14:1231-1247, (2000)
	39	Smith et al., "Gastrin and gastrin receptor activation: an early event in the adenoma-carcinoma sequence," Gut, 47(6):820-824, (2000)

Examiner Initial	Document No.	Document
	40	Smith et al., "Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer," Clinical Cancer Research, 6(12):4719-4724, (2000)
	41	Takhar et al., "The role of gastrin in colorectal carcinogenesis" J. R. Coll. Surg. Edinb. Irel. 2(5):251-257 (2004)
	42	Varro et al., "Gastrin: an analytical review" Ann. Clin. Biochem. 40, 472-480 (2003)
	43	Von Hoff et al., "New drugs for patients with pancreatic cancer" Curr. Opin. Oncology 14:621-627 (2002)
	44	Watson et al., "Antibodies raised by gastrimmune inhibit the spontaneous metastasis of a human colorectal tumour AP5LV," European Journal of Cancer, 35(8):1286-1291, (1999)
	45	Watson et al., "Antiserum raised against an epitope of the cholecystokinin B/gastrin receptor inhibits hepatic invasion of a human colon tumor," Cancer Research, 60(20):5902-5907, (2000)
	46	Watson et al., "Enhanced inhibition of Pancreatic Cancer by Combination of the G17DT Immunogen and Gemcitabine" Amer. Soc. Clin. Oncol. Abstract 37 (2002)
	47	Watson et al., "Hypergastrinemia promotes adenoma progression in the APCMin-/+ Mouse Model of Familial Adenomatous Polyposis," Cancer Research, 61:625-631, (2001).
	48	Watson, S.A. and A.D. Gilliam, "A new weapon in the therapeutic armoury for gastrointestinal malignancy," Expert Opinion on Biological Theory, 1(2):309-317,(2001)
	49	Watson et al., "Synergistic inhibitory effects of G17DT on gastrointestinal tumor growth in combination with cytotoxic agents" Proc. Am. Soc. Clin. Oncol. 22:2003 (abstr 3497) (2003)
	50	Yardley, "Gemcitabine and docetaxel in metastatic and neoadjuvant treatment of breast cancer" Semin Oncol. 31:(2 Suppl 5):37-44 (2004)

Applicant also makes known to the Examiner the following U.S. and international applications, which are commonly owned and/or have one or more inventors in common:

<u>Serial No.</u>	<u>Filing Date</u>	<u>Docket No.</u>
10/762,226	01/20/04	17118-056002/ 2835B
10/235,236	09/04/02	17118-057002/ 2836B
10/323,692	12/19/02	17118-057003/ 2836C
10/098,690	03/15/02	17118-058002/ 2837B
10/829,137	04/21/04	17118-059US2/ 2838BUS

Applicant : Gevas et al.
Serial No. : 09/700,402
Filed : May 4, 2001


Attorney's Docket No.: 17118-061US1 / 2840US
Supplemental Information Disclosure Statement

11/252,904	10/18/05	17118-060US3/ 2839CUS
11/360,378	02/22/06	17118-062002/ 2841B
10/192,257	07/09/02	17118-063001/ 2842
10/813,336	03/29/04	17118-064001/ 2843
11/499,261	08/03/06	17118-064003/ 2843C
11/808,889	05/07/07	17118-064004/ 2843D
11/659,937	02/09/07	17118-066US1/ 2845US
11/663,126	03/16/07	17118-067US1/ 2846US
11/036,690	01/14/05	17118-073003/ 2849C
11/489,775	07/20/06	17118-073004/ 2849D
11/492,695	07/25/06	17118-073005/ 2849E
PCT/IB2006/001572	06/13/06	17118-068WO1/ 2847PC

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the documents or information, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(g) and (h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing documents and they be made of record in the file history of the above-captioned application.

Respectfully submitted,


Stephanie Seidman
Reg. No. 23,778

Attorney's Docket No.: 17118-061US1/2840US
Address all correspondence to:
Stephanie Seidman
Fish & Richardson P.C.
12390 El Camino Real
San Diego, California 92130
Telephone: (858) 678-4777
Facsimile: (202) 626-7796
email: seidman@fr.com

Substitute Form PTO-1449
(Modified)

SEP 27 2007

U.S. Department of Commerce
Patent and Trademark OfficeAttorney's Docket No.
17118-061US1/2840USApplication No.
09/700,402**List of Patents and Publications for Applicant's
Information Disclosure Statement**Applicant
Gevas et al.Filing Date
May 4, 2001Group Art Unit
1643

(37 CFR §1.98(b))

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	2001/0020005	09/06/01	Chowers et al.	514	008	12/15/00
	AB	2002/0058040	5/16/02	Grimes et al.	424	185.1	12/22/00
	AC	2002/0095028	7/18/02	Grimes et al.	530	412	03/15/02
	AD	2003/0021786	01/30/03	Gevas et al.	424	146.1	07/09/02
	AE	2003/0068326	04/10/03	Gevas et al.	424	185.1	12/06/02
	AF	2003/0086941	05/08/03	Michaeli et al.	424	185.1	09/04/02
	AG	2003/0091574	05/15/03	Gevas et al.	424	155.1	03/22/02
	AH	2004/0001842	01/01/04	Michaeli et al.	424	185.1	12/19/02
	AI	2005/0025770	02/03/05	Gevas et al.	424	155.1	01/20/04
	AJ	2005/0069966	03/31/05	Grimes et al.	435	7.92	03/29/04
	AK	2005/0169979	08/04/05	Michaeli et al.	424	184.100	01/14/05
	AL	2005/0187152	08/25/05	Gevas et al.	514	12	04/21/04
	AM	2006/0020119	01/26/06	Grimes et al.	530	388.24	03/29/05
	AN	2006/0039911	02/23/06	Gevas et al.	424	145.1	10/18/05
	AO	2006/0140962	06/29/06	Gevas et al.	424	155.1	02/22/06
	AP	2007/0065454	03/22/07	Michaeli et al.	424	184.1	07/20/06
	AQ	2007/0082043	04/12/07	Michaeli et al.	424	184.1	07/25/06
	AR	3,931,141	01/06/76	Wissmann	530	329	11/15/73
	AS	4,201,770	05/06/80	Stevens	424	177	08/25/78
	AT	4,302,386	11/24/81	Stevens	260	112.5	04/15/85
	AU	4,384,995	05/24/83	Stevens	260	112.5	11/20/81
	AV	4,526,716	07/02/85	Stevens	260	112.5	03/04/83
	AW	4,565,805	01/21/86	Smirnov	514	17	11/20/84
	AX	4,687,759	08/18/87	Martinez	514	18	12/16/85
	AY	4,691,006	09/01/87	Stevens	530	324	11/02/84
	AZ	4,713,366	12/15/87	Stevens	514	13	12/04/85
	BA	4,762,913	08/09/88	Stevens	530	345	07/15/87

Examiner Signature

Date Considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17118-061US1/2840US		Application No. 09/700,402	
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))				Applicant Gevas et al.			
				Filing Date May 4, 2001		Group Art Unit 1643	
U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	BB	4,767,842	08/30/98	Stevens	530	324	07/15/87
	BC	4,794,103	12/27/88	Bertolini	514	12	01/02/87
	BD	4,840,939	06/20/89	Leveen et al.	514	25	03/18/87
	BE	4,925,922	05/15/90	Byers et al.	424	182.1	05/08/89
	BF	4,971,792	11/20/90	Steplewski et al.	424	1.49	03/27/87
	BG	4,978,683	12/18/90	Rovati et al.	514	617	12/05/85
	BH	4,997,950	03/05/91	Murphy et al.	548	304.1	04/20/89
	BI	5,006,334	04/09/91	Stevens	424	88	07/15/87
	BJ	5,055,404	10/08/91	Ueda et al.	530	388.8	08/07/89
	BK	5,162,504	11/10/92	Horoszewicz	530	388.2	06/03/88
	BL	5,484,596	01/16/96	Hanna, Jr. et al.	424	277.1	11/01/93
	BM	5,585,474	12/17/96	Iwaki et al.	536	22.1	11/13/95
	BN	5,607,676	03/04/97	Gevas et al.	424	197.11	07/22/91
	BO	5,609,870	03/11/97	Gevas et al.	424	184.1	08/04/94
	BP	5,622,702	04/22/97	Gevas et al.	424	184.1	03/30/94
	BQ	5,665,864	09/09/97	Quaranta et al.	530	387.1	09/02/94
	BR	5,665,874	09/09/97	Kuhajda et al.	536	24.3	06/05/95
	BS	5,688,506	11/18/97	Grimes et al.	424	184.1	01/27/94
	BT	5,698,201	12/16/97	Stevens	424	195.11	06/06/95
	BU	5,703,213	12/30/97	Wands et al.	530	388.85	02/07/94
	BV	5,712,369	01/27/98	Old et al.	530	350	02/02/96
	BW	5,750,119	05/12/98	Srivastava	424	277.1	09/30/94
	BX	5,759,551	06/02/98	Ladd et al.	424	198.100	12/26/95
	BY	5,785,970	07/28/98	Gevas et al.	424	184.1	06/05/95
	BZ	5,786,213	07/28/98	Singh et al.	435	320.100	04/18/96
	CA	5,827,691	10/27/98	Iwaki et al.	435	69.1	04/09/97
	CB	5,866,128	02/02/99	Gevas et al.	424	184.1	06/05/95

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified) List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17118-061US1/2840US	Application No. 09/700,402
	Applicant Gevas et al.		
	Filing Date May 4, 2001	Group Art Unit 1643	

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	CC	5,869,045	02/09/99	Hellstrom et al.	424	130.1	06/02/95
	CD	5,879,898	03/09/99	Tarin et al.	435	7.21	05/17/95
	CE	5,843,446	12/01/98	Ladd et al.	424	184.1	06/07/95
	CF	6,132,720	10/17/00	Grimes et al.	424	184.100	11/17/97
	CG	6,169,173	01/02/01	Wank	536	23.5	03/10/93
	CH	6,187,536	02/13/01	Weinberg et al.	435	6	02/18/98
	CI	6,191,290	02/20/01	Safavy	549	510	02/23/00
	CJ	6,303,123	10/16/01	Grimes et al.	424	184.1	06/07/95
	CK	6,359,114	03/19/02	Grimes et al.	530	344	06/07/95
	CL	6,548,066	04/15/03	Michaeli et al.	424	185.1	05/12/98
	CM	6,696,262	02/24/04	Harkonen	435	7.32	03/14/01
	CN	6,815,414	11/09/04	Chowers et al.	514	8	12/15/00
	CO	6,861,510	03/01/05	Gevas et al.	530	388.1	06/06/95

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	CP	90/08774	08/09/90	WIPO				
	CQ	94/00590	01/06/94	WIPO				
	CR	95/13297	05/18/95	WIPO				
	CS	95/21380	08/10/95	WIPO				
	CT	96/15456	05/23/96	WIPO				
	CU	97/38584	10/23/97	WIPO				
	CV	99/19353	04/22/99	WIPO				
	CW	99/59612	11/25/99	WIPO				
	CX	99/59628	11/25/99	WIPO				
	CY	99/59631	11/25/99	WIPO				
	CZ	99/65513	12/23/99	WIPO				

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17118-061US1/2840US	Application No. 09/700,402
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Gevas et al.	
		Filing Date May 4, 2001	Group Art Unit 1643

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	DA	00/67035	11/09/00	WIPO				
	DB	01/34192	05/17/01	WIPO				
	DC	2006/008649	01/26/06	WIPO				
	DD	2006/016275	02/16/06	WIPO				
	DE	2006/032980	03/30/06	WIPO				
	DF	380230	11/17/94	EP				
	DG	1129724	09/05/01	EP				

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	DH	"ADAP drugs: leucovorin," Access Project, http://www.aegis.com/factshts/network/access/drugs/leuc.html (1996) (accessed on 8.13.04), 1 page.
	DI	Abrahm et al., "Development and evaluation of a high affinity species and region specific monoclonal antibody to human gastrin," Gastroenterology, 86(5(2)):1012, (1984).
	DJ	Ajani et al., "Phase I and II Studies of the Combination of Recombinant Human Interferon- and 5-Fluorouracil in Patients with Advanced Colorectal Carcinoma" Journal of Biological Response Modifiers, 8(2):140-146, (1989).
	DK	Ardill et al., "Autoantibodies to gastrin in patients with pernicious anaemia – a novel antibody," Quarterly Journal of Medicine, 91:739-742, (1988).
	DL	Asao et al., "Eradication of Hepatic Metastases of Carcinome H-59 combination chemimmunotherapy with Liposomal Muramyl Tripeptide, 5-Fluorouracil, and Leucovorin," Cancer Research, 52:6254-6257, (1992).
	DM	Ausubel, ed., "Current Protocols in Molecular Biology," John Wiley & Sons, New York, pp 11.15.1-11.15.4. (1990)
	DN	Azuma et al., "Immunocytochemical evidence for differential distribution of gastrin forms using region-specific antibodies," Gastroenterologia Japonica, 21(4):319-324, (1986).
	DO	Baldwin, G.S. and A. Shulkes, "Gastrin receptors and colorectal carcinoma," Gut, 42:581-584, (1998).
	DP	Ballantyne et al. "Surgical treatment of liver metastasis in patients with colorectal cancer," Cancer, 71(12): 4252-4266, (1993).
	DQ	Beacham et al., "Human gastrin: isolation, structure and synthesis: synthesis of human gastrin I," Nature, 209(5023):585-586, (1966).
	DR	Beauchamp et al., "Proglumide, a gastrin receptor antagonist, inhibits growth of colon cancer and enhances survival in mice," Annals of Surgery, 202:303-309, (1985).
	DS	Beinborn et al., "A single amino acid of the CCKB/gastrin receptor determines specificity for non-peptide antagonists," Nature, 362:348-350, (1993).

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17118-061US1/2840US	Application No. 09/700,402
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Gevas et al.	
		Filing Date May 4, 2001	Group Art Unit 1643

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	DT	Bentley et al., "Human gastrin: isolation, structure and synthesis: structures of human gastrins I and II," Nature, 209(5023):583-585, (1966).
	DU	Biagini et al., "The human gastrin/cholecystokinin receptors: Type B and type C expression in colonic tumours and cell lines," Life Sciences, 61(10):1009-1018, (1997).
	DV	Blackmore, M., et al. "Autocrine growth stimulation of human renal Wilms' tumour G401 cells by a gastrin-like peptide," International Journal of Cancer, 57:385-391, (1994).
	DW	Boland, "Gastrin and colorectal neoplasia--chicken or egg, or both" Journal of Clinical Gastroenterology, 13(5):497-499, (1991).
	DX	Bold et al., "Gastrin stimulates growth of human colon cancer cells via a receptor other than CCK-A or CCK-B," Biochemical and Biophysical Research Communications, 202(3):1222-1226, (1994).
	DY	Boon, T., "Toward a Genetic Analysis of Tumor Rejection Antigens," Advanced Cancer Research, 58:177-210, (1992).
	DZ	Bowie et al., "Deciphering the message in protein sequences: tolerance to amino acid substitutions," Science, 247:1306-1310, (1990).
	EA	Brett et al., "Lymphocyte expression of the CCK-B/gastrin receptor (CCK-BR) in gastric lymphomas, Helicobacter pylori gastritis and normal gastric biopsies," Gastroenterology, 114: (Supplement 1): A570 (Abstract #G2333) (April 15, 1998).
	EB	Brett et al., "The effect of antibodies raised against gastrin on the proliferation of human pancreatic carcinoma cell lines," Gut, 42(Suppl.):A26 (Abstract # W190) (1998).
	EC	Buchan, A., et al., "Regulatory peptides in Barrett's esophagus," Journal of Pathology, 146(3):227-234, (1985).
	ED	Burris III et al., "Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial," Journal of Clinical Oncology, 15(6):2403-2413 (1997).
	EE	Bystryn, J., "Tumor vaccines," Cancer and Metastasis Reviews, 9:81-91, (1990).
	EF	Caplin et al., "Expression and processing of gastrin in hepatocellular carcinoma, fibromellar carcinoma and cholangiocarcinoma," Journal of Hepatology, 30(3):519-526, (1999).
	EG	Caplin et al., "Serum gastrin levels and identification of CCK-B-gastrin receptor following partial hepatectomy for liver tumours in man," Gastroenterology, 110(4 suppl.) A1162, (1996).
	EH	Caplin et al., "Expression and processing of gastrin in patients with hepatocellular carcinoma, fibrolamellar carcinoma and cholangiocarcinoma," Gastroenterology 114(Supplement 1): A1219 (Abstract # L0083) (April 15, 1998).
	EI	Caplin et al., "Expression and processing of gastrin in patients with pancreatic carcinoma," Gastroenterology 114(Supplement 1): A445 (Abstract # G1809) (April 15, 1998).
	EJ	Caplin et al., "Targeted radiopeptide therapy: High dose indium-111 octreotide for neuroendocrine tumours," Gastroenterology, 114(Supplement 1): A574 (Abstract # G2348) (April 15, 1998).
	EK	Casper et al., "Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas," Investigational New Drugs, 12(1):29-34, (1994) (Abstract).
	EL	Choudhury et al., "N-Terminal sequence of human big gastrin: Sequence, synthetic and immunochemical studies," A76 Hoppe-Seyler's Z. Physiol. Chem., 361:1719-1733, (1980).
	EM	Clerc et al., "Differential expression of the CCK-A and CCK-B/Gastrin receptor genes in human cancers of the esophagus, stomach, and colon," International Journal of Cancer, 72:931-936, (1997).

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17118-061US1/2840US	Application No. 09/700,402
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))				Applicant Gevas et al.	
				Filing Date May 4, 2001	Group Art Unit 1643
Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner Initial	Desig. ID	Document			
	EN	de Jong et al. "Effects of partial liver resection on tumor growth," Journal of Hepatology, 25:109-121, (1996).			
	EO	De Magistris et al., "A simple enzymatic procedure for radioimmunochemical quantitation of the large molecular forms of gastrin and cholecystokinin," Analytical Biochemistry, 102:126-133, (1980).			
	EP	de Weerth et al., "Human pancreatic cancer cell lines express the CCKB receptor," Hepatogastroenterology, 46:472-478, (Jan-Feb 1999).			
	EQ	Del Valle et al., "Progastrin and its glycine-extended posttranslational processing intermediates in human gastrointestinal tissues," Gastroenterology, 92:1908-1912, (1987).			
	ER	Dethloff et al., "Inhibition of gastrin-stimulated cell proliferation by the CCK-B/gastrin receptor ligand CI-988," Food and Chemical Toxicology, 37:105-110, (1999).			
	ES	DeWeerth et al., "Human pancreatic cancer cell lines express the CCKB/gastrin receptor," Gastroenterology, A289, (1994).			
	ET	Dockray et al., "Amino-terminal gastrin fragment in serum of Zollinger-Ellison syndrome patients," Gastroenterology, 68(2):222-230 (1975).			
	EU	Dockray et al., "Gastric endocrine cells: gene expression, processing, and targeting of active products," Physiological Review, 76(3):767-798, (1996).			
	EV	Dockray et al., "Heptadecapeptide gastrin: measurement in blood by specific radioimmunoassay," Gastroenterology, 71(6):971-977, (1976).			
	EW	Dockray et al., "Immunochemical studies on big gastrin using NH2-terminal specific antisera," Chemical Abstracts 94:506-507, (1981) [Abstract #94:119200w].			
	EX	Dockray et al., "Immunochemical studies on big gastrin using NH2-terminal specific antisera," Regulatory Peptides 1:169-186 (1980).			
	EY	Douziech et al., "Growth effects of regulatory peptides and intracellular signaling routes in human pancreatic cancer cell lines," Endocrine, 9:171-183, (1998).			
	EZ	Edgington, "Biotech Vaccines' Problematic Promise," Bio/Technology, 10:763-766 (1992).			
	FA	Edkins, J.S., "On the chemical mechanism of gastric secretion," Proceedings of the Royal Society of London. Series B, Containing papers of a Biological character, 76:376, (1905).			
	FB	Edkins, J.S., "The chemical mechanism of gastric secretion," Journal of Physiology, 34(1-2):133-144, (1906).			
	FC	Erlichman et al., "A randomized trial of fluorouracil and folonic acid in patients with metastatic CRC," Journal of Clinical Oncology, 6:469-475, (1988).			
	FD	Ezzell, C., "Cancer 'Vaccines': An Idea Whose Time as Come?," Journal of NIH Research, 7:46-49, (1995).			
	FE	Feurle et al., "The role of CCK and its analogues in the organogenesis of the fetal rat pancreas," Pancreas, 10:281-286, (1995).			
	FF	Fourmy et al., "Relationship of CCK/gastrin receptor binding to amylase release in dog," Regulatory Peptides, 10:57-68, (1984).			
	FG	Frucht et al., "Characterization of functional receptors for gastrointestinal hormones on human colon cancer cells," Cancer Research, 52(5):1114-1122, (1992).			
	FH	Goletti et al., "Resection of liver gastrinoma leading to persistent Eugastrinemia" Eur. J. Surgery 158:55-57 (1992).			
Examiner Signature			Date Considered		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17118-061US1/2840US	Application No. 09/700,402
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Gevas et al.	
		Filing Date May 4, 2001	Group Art Unit 1643

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	FI	Gregory et al., "Isolation of two gastrins from human antral mucosa," Nature, 209(5023):583, (1966).
	FJ	Grider, "Distinct receptors for cholecystokinin and gastrin," American Journal of Physiology, 259:G184-G190 (1990).
	FK	Gupta, R. and G. Siber, et al., "Adjuvants for human vaccines - current status, problems and future prospects," Vaccine, 13(14):1263-1276, (1995).
	FL	Gura, T., "Systems for Identifying New Drugs Are Often Faulty," Science, 278(5340):1041-1042, (1997).
	FM	Halter et al., "Evaluation of a monoclonal anti-gastrin antibody as a tool for immunoneutralization of gastrin during omeprazole treatment in the rat," Gastroenterology, 96(5) part 2:A194, (1989).
	FN	Helander et al., "Immunohistochemical localization of gastrin/CCK-B receptors in the dog and guinea-pig stomach," Acta Physiologica Scandinavica, 159(4):313-320, (1997).
	FO	Herbert et al. (Eds.) "The Dictionary of Immunology," 3rd Ed. Academic Press, London, p. 41, (1995).
	FP	Herget et al., "Cholecystokinin stimulates Ca ²⁺ mobilization and clonal growth in small cell lung cancer through CCKA and CCKB/gastrin receptors," Annals of the New York Academy of Sciences, 713:283-297, (1994).
	FQ	Hoosein et al., "Anti-proliferative effects of gastrin receptor antagonists and antibodies to gastrin on human colon carcinoma cell lines" Cancer Res.48:7179-7183 (1988).
	FR	Hoosein et al., "Evidence for Autocrine Growth Stimulation of Cultured Colon Tumor Cells by a Gastrin/Cholecystokinin-like Peptide," Experimental Cell Research, 186(1):15-21, (1990).
	FS	Houghton, R.A., et al., "Relative importance of position and individual amino acid residues in peptide antigen-antibody interactions: implications in the mechanism of antigenic drift and antigenic shift," In Vaccine, 86:21-25, (1986) (Brown et al. eds).
	FT	Hughes et al., "Therapy with gastrin antibody in the Zollinger-Ellison Syndrome," Digestive Diseases, 21:201-204, (1976).
	FU	Ichikawa et al., "Distinct effects of tetragastrin, histamine, and CCh on rat gastric mucin synthesis and contribution of NO," American Journal of Physiology, 274(1):G138-G146, (1998).
	FV	Iwanaga et al., "Immunocytochemical localization of the different gastrin forms in the pyloric antrum," Biomedical Research, 1:316-320, (1980).
	FW	Iwase et al., "Regulation of growth of human gastric cancer by gastrin and glycine-extended pro-gastrin," Gastroenterology, 113:782-790, (1997).
	FX	Jaffe et al., "Gastrin resistance following immunizations to the C-terminal tetrapeptide amide of gastrin," Surgery, 69(2):232-237, (1971).
	FY	Jaffe et al., "Inhibition of endogenous gastrin activity by antibodies to the carboxyl terminal tetrapeptide amide of gastrin," Gastroenterology, 58:151-156, (1970).
	FZ	Jaffe et al., "Inhibition of endogenous gastrin activity by incubation with antibodies to the C-terminal tetrapeptide of gastrin," Surgery, 65: 633-639, (1969).
	GA	Jain, R.K., "Barriers to drug delivery in solid tumors," Scientific American, 171(1):58-65, (1994).
	GB	Johnson, "New aspects of the trophic action of gastrointestinal hormones," Gastroenterology, 72:788-792, (1977).

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17118-061US1/2840US	Application No. 09/700,402
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Gevas et al.	
		Filing Date May 4, 2001	Group Art Unit 1643

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	GC	Joshi et al., "Gastrin and colon cancer: a unifying hypothesis," Digestive Diseases, 14:334-344, (1996).
	GD	Justin, T. and R. Steele et al., "Gastric acid suppression using anti-gastrin 17 antibodies produced by a gastrin immunogen, Gastrimmune, in an in vivo pig model," Gastroenterology, 108(4): A125, (1995).
	GE	Kameyama et al., "Adjuvant Chemo-endocrine chemotherapy with gastrin antagonist after resection of liver metastasis in colorectal cancer," Gan. To. Kagaku Ryoho [Japanese Journal of Cancer and Chemotherapy], 21(13):2169-2171, (1994) [in Japanese, English summary on last page of article].
	GF	Katoh et al., "Malignant Zollinger-Ellison Syndrome. Stabilizing of liver metastasis after gastrectomy with resection of primary tumor," American Surgeon, 56(6):360-363, (1990).
	GG	Kaufmann et al., "Cholecystokinin B-type receptor signaling is involved in human pancreatic cancer cell growth," Neuropeptides, 31(6):573-583 (1997).
	GH	Kelley et al., "Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer," Chest, 112:256-261, (1997).
	GI	Kobori et al., "Growth response of rat stomach cancer cells to gastro-entero-pancreatic hormones," International Journal of Cancer, 30:65-67, (1982).
	GJ	Koh et al., "Gastrin deficiency results in altered gastric differentiation and decreased colonic proliferation in mice," Gastroenterology, 113(3):1015-1025, (1997).
	GK	Koh et al., "Glycine-Extended Gastrin Promotes the Growth of a human hepatoma cell line," Gastroenterology, 110(4):1089, (1996).
	GL	Kothary et al., "NH2-terminal of gastrin-17 in duodenal ulcer disease: Identification of progastrin-17," Biochemical and Biophysical Research Communications, 146(2):884-888, (1987).
	GM	Kothary et al., "Identification of gastrin molecular variants in gastrinoma syndrome," Regulatory Peptides, 17:71-84, (1987).
	GN	Kovacs et al. "Inhibition of sham feeding-stimulated acid secretion in dogs by immunoneutralization of gastrin" Am. J. Physiol. 273 (2 Pt 1):G399-403 (1997).
	GO	Kovacs et al., "Gastrin is a major mediator of the gastric phase of acid secretion in dogs: Proof by monoclonal antibody neutralization" Gastroenterology 97:1406-1413 (1989).
	GP	Kovacs et al., "Gastrin partially mediates insulin-induced acid secretion in dogs," Peptides, 17(4):583-587, (1996).
	GQ	Kusyk et al., "Stimulation of growth of a colon cancer cell line by gastrin", Am. J. Physiol. 251:G597-G601 (1986).
	GR	Lamers et al., "Role of gastrin and cholecystokinin in tumors of the gastrointestinal tract", Eur. J. Cancer Clin. Oncol. 24(2):267-273 (1988).
	GS	Lamote et al., "Stimulating effect of pentagastrin on cancer cell proliferation kinetics in chemically induced colon cancer in rats" Regulatory Peptides 20:1-9 (1988).
	GT	Larsson et al. "Characterization of antral gastrin cells with region-specific antisera". J. Histochem. Cytochem. 25:1317-1321 (1977).
	GU	Larsson, "Histochemistry of gastrin cells", Neurohistochem.: Modern Meth. and App. Alan R. Liss, Inc.:527-567 (1986).
	GV	Le Meuth et al., "Differential expression of A- and B-subtypes of cholecystokinin/gastrin-receptors in the developing calf pancreas" Endocrinology 133:1182-1191 (1993).

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17118-061US1/2840US		Application No. 09/700,402	
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))				Applicant Gevas et al.			
				Filing Date May 4, 2001		Group Art Unit 1643	
Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner Initial	Desig. ID	Document					
	GW	Lee et al., "The Human Brain Cholecystokinin-B/Gastrin Receptor" J. Biol. Chem. 268(11):8164-8169 (1993).					
	GX	MacKenzie et al., "Development of a radioligand binding assay to characterize gastrin receptors in the human gastrointestinal tract" Gut 38:A37 (Abstract T146) (1996).					
	GY	Makishima et al., "Active immunization against gastrin-17 with an N-terminal derived immunogen inhibits gastric and duodenal lesions in rats" Gastroenterology 106(4/2):A824 (1994) [Abstract]					
	GZ	Makishima et al., "Inhibition of Gastrin-17 Stimulated acid secretion through active immunization in rats" FASEB J. 8:A92, Abs. 535 (1994).					
	HA	Mandair et al., "Cholecystokinin receptors in human pancreatic cancer cell lines" Eur. J. Cancer 34:1455-1459 (1998).					
	HB	Marino et al. "Expression and post-translational processing of gastrin in heterologous endocrine cells" J. Biol. Chem. 266(10):6133-6136 (1991).					
	HC	Matsumoto et al. "Gastrin receptor characterization: affinity cross-linking of the gastrin-receptor on canine gastric parietal cells" Am J. Physiol. 252:G143 (1987).					
	HD	McGregor et al., "Trophic effects of gastrin on colorectal neoplasms in the rat", Ann. Surg. 195(2):219-223 (1982).					
	HE	McRae et al., "Role of gastrin and gastrin receptors in the growth of human colon carcinoma cells" J. Cell Biol. 103(22a): 74 (1986).					
	HF	McWilliams et al., "Coexpression of Gastrin and Gastrin Receptors (CCK-B and CCK-B) in gastrointestinal tumour cell lines" Gut 42:795-798 (1998).					
	HG	Miyake, "A truncated isoform of human CCK-B/gastrin receptor generated by alternative usage of a novel exon" Biochem. Biophys. Commun. 208(1):230-237 (1995).					
	HH	Mizutani et al. "Promotion of hepatic metastases by liver resection in the rat" British J. Cancer 65(6):794-797 (1992).					
	HI	Moody et al., "GRP receptors are present in non small cell lung cancer cells," Journal of Cellular Biochemistry Supplement, 24:247-256, (1996).					
	HJ	Moroder et al. "Gastrins and cholecystokinins: Chemical and immunological aspects", Gastrin and Cholecystokinin, Chem., Physio. and Pharma. (Ed. J.. Bali et al.) Elsevier Science Publishers B.V.:21-32 (1987).					
	HK	Mu et al., "Monoclonal antibody to the gastrin receptor on parietal cells recognizes a 78-kDa protein", Proc. Natl. Acad. Sci. 84:2698-2702 (1987).					
	HL	Mulholland et al., "Elevated Gastric Acid Secretion in Patients with Barrett's Metaplastic Epithelium" Digestive Diseases and Sciences, 34(9):1329-1334, (1989).					
	HM	Nakata et al., "Cloning and characterization of gastrin receptor from ECL carcinoid tumor of Mastomys natalensis" Biochem. Biophys. Res. Comm. 187:1151 (1992).					
	HN	Narayan et al., "Characterization of gastrin binding to colonic mucosal membranes of guinea pigs" Mol. Cell. Biochem. 112:163-171 (1992).					
	HO	Negre et al., "Autocrine stimulation of AR4-2J rat pancreatic tumour cell growth by glycine-extended gastrin" Int. J. Cancer 66(5):653-658 (1996).					
	HP	Nemeth et al., "A gastrin aminoterminalis 1-13 fragmensével kidolgozott, szekvenciaspecifkus radioimmunoassay", Izotoptechnika 25(4):288-294 (1982).					
	HQ	Nemeth et al., "Development of a sequence-specific radioimmunoassay by using N-terminal gastrin 1-13 antibody", Chemical Abstracts 98:495 (1983) [Abstract #98:51653w].					
Examiner Signature				Date Considered			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17118-061US1/2840US	Application No. 09/700,402
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))				Applicant Gevas et al.	
				Filing Date May 4, 2001	Group Art Unit 1643
Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner Initial	Desig. ID	Document			
	HR	Nieschlag, "Immunization with hormones in reproduction research", North Holland Publishing, pp. 107-117 (1975).			
	HS	Ochiai et al., "Growth-promoting effect of gastrin on human gastric carcinoma cell line TMK-1" Japan J. Can. Res. 76:1064-1071 (1985).			
	HT	Ohkura et al., "Gastrin-enhanced tumor growth of a xenotransplantable human gastric carcinoma in nude mice" Jpn. J. Clin. Oncol. 10(2):255-263 (1980).			
	HU	Ohning et al., "Differential kinetics for immunoneutralization of circulating gastrin by gastrin monoclonal antibody and its Fab1 fragment in rats" Peptides 15:417-423 (1994).			
	HV	Ohning et al., "Gastrin mediates the gastric mucosal proliferative response to feeding," American Journal of Physiology, 271(3(1)):G470-G476, (1996).			
	HW	Okada et al., "Evaluation of cholecystokinin, gastrin, CCK-A receptor and CCK-B/gastrin receptor gene expressions in gastric cancer" Cancer Letters 106(2):257-262 (1996).			
	HX	Osband et al., "Problems in the investigational study and clinical use of cancer immunotherapy," Immunology Today, 11:193-195, (1990).			
	HY	Palnaes et al., "Metabolism and influence of glycine-extended gastrin on gastric acid secretion in man" Digestion 57:22-29 (1996).			
	HZ	Parsonnet et al., "Helicobacter pylori infection and the risk of gastric carcinoma" N. Engl. J. Med. 325:1127-1131 (1991).			
	IA	Pawlikowski et al., "Gastrin and somatostatin levels in patients with gastric cancer", Horm. Metabol. Res. 21:89-91 (1989).			
	IB	Petrioni et al., "Treatment of advanced colorectal cancer with high-dose intensity folinic acid and 5-Fluorouracil plus supportive care", Eur. J. Cancer 31A:2105-2108 (1995).			
	IC	Power et al., "A novel gastrin-processing pathway in mammalian antrum", Chemical Abstracts 109(9):113 (1988) [Abstract #109:67341z].			
	ID	Rae-Venter et al., "Gastrin receptors in human colon carcinoma", Gastroenterology 80(5/2):1256 (1981).			
	IE	Rahier et al., "Biosynthesis of Gastrin. Localization of the precursor and peptide products using electron microscopic-immunogold methods," Gastroenterology, 92:1146-1152, (1987).			
	IF	Redmond et al. in "Gastroesophageal Reflux Disease" Ronald Hinder ed., R.G. Landes Co., pp1-6 (1993).			
	IG	Rehfeld et al., "Cell-specific processing of pro-cholecystokinin and pro-gastrin" Biochimie 70:25-31 (1988).			
	IH	Rehfeld et al., "Production and evaluation of antibodies for the radioimmunoassay of gastrin", Scand. J. Clin. Lab. Invest. 30:221-232 (1972).			
	II	Rehfeld et al., "Residue-specific immunochemical sequence prediction" Journal of Immunological Methods, 171:139-142, (1994).			
	IJ	Rehfeld et al., "Sulfation of gastrin: Effect on immunoreactivity", Regulatory Peptides 2:333-342 (1981).			
	IK	Rehfeld, J.F., "Gastrin and Colorectal Cancer: A Never-Ending Dispute," Gastroenterology, 108(4):1307-1310, (1995).			
	IL	Roberston et al., "Effect of gastrointestinal hormones and synthetic analogues on the growth of pancreatic cancer" Int. J. Cancer 63:69-75 (1995).			

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17118-061US1/2840US	Application No. 09/700,402
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Gevas et al.	
		Filing Date May 4, 2001	Group Art Unit 1643

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	IM	Rodriguez-Lescure et al., "Phase II Study of Gemcitabine (GEM) and Weekly 48 Hour Continuous Infusion (CI) with High Dose 5-Fluorouracil in Advanced Exocrine Pancreatic Cancer (APC)" Proceedings of the Annual Meeting of the American Society of Clinical Oncology 18:298 abstract 1145 (1999).
	IN	Romani et al., "Gastrin Receptor Antagonist CI-988 Inhibits growth of Human Colon Cancer in vivo and in vitro", AZN J. Surgery 66:235-237 (1996).
	IO	Romani et al., "Potent new family of gastrin receptor antagonists (GRAs) produces in vitro and in vivo inhibition of human colorectal cancer cell lines" Procs. AACR, 35:397 (Abstract) (1994).
	IP	Rothenberg et al., "A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer" Annals of Oncology 7:347-353 (1996).
	IQ	Scemama et al., "Characterization of gastrin-receptors on a rat pancreatic acinar cell line (AR4-2J). A possible model for studying gastrin mediated cell growth and proliferation" Gut 28:233-236 (1987).
	IR	Scheele et al., "Indicators of prognosis after hepatic resection for colorectal cancers," Surgery, 110 (I):13-29 (1991).
	IS	Scheithauer et al., "Combined intraperitoneal plus intravenous chemotherapy after curative resection for colonic adenocarcinoma" Eur. J. Cancer 31A:1981-1986 (1995).
	IT	Seitz et al., "Elevated serum gastrin levels in patients with colorectal neoplasia" J. Clin. Gastroenterol. 13(5):541-545 (1991).
	IU	Seva et al., "Characterization of the glycine-extended gastrin (G-gly) receptor on AR-42J cells" Gastroenterology A1005 (1995).
	IV	Seva et al., "Lorglumide and loxglumide inhibit gastrin-stimulated DNA synthesis in a rat tumoral acinar pancreatic cell line (AR42J). Cancer Res. 50(18):5829-5833 (1990).
	IW	Siemann, "Satisfactory and unsatisfactory tumor models: Factors influencing the selection of a tumor model for experimental evaluation", Rodent Tumor Models in Experimental Cancer Therapy (Ed. Kallman) Pergamon Press, NY: 12-15 (1987).
	IX	Singh et al., "Gut hormones in colon cancer: past and prospective studies" Cancer J. 3:28-33 (1990).
	IY	Singh et al., "High levels of progastrin significantly increase premalignant changes in colonic mucosa of mice in response to the chemical carcinogen, AOM" Gastroenterology 114(4):A680 (1998).
	IZ	Singh et al., "Incomplete processing of progastrin expressed by human colon cancer cells: roles of noncarboxyamidated gastrins" The American Physiological Society G459-G468 (1994).
	JA	Singh et al., "Novel gastrin receptors mediate mitogenic effects of gastrin and processing intermediates of gastrin on Swiss 3T3 fibroblasts. Absence of detectable cholecystokinin (CCK)-A and CCK-B receptors" J. Biol. Chem. 270:8429-8435 (1995).
	JB	Singh et al., "Role of gastrin and gastrin receptors on the growth of a transplantable mouse colon carcinoma (MC-26) in BALB/c Mice" Cancer Res. 46, 1612-1616 (1986).
	JC	Smith et al., "Gastrin regulates the growth of human pancreatic cancer in a tonic and autocrine fashion" Amer. J. Physiol. 270(5):R1078-R1084 (1996).
	JD	Smith et al., "Identification and characterization of CCK-B/gastrin receptors in human pancreatic cancer cell lines" Amer. J. Physiol. 266:R277-283 (1994).

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17118-061US1/2840US		Application No. 09/700,402	
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))				Applicant Gevas et al.			
				Filing Date May 4, 2001		Group Art Unit 1643	
Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner Initial	Desig. ID	Document					
	JE	Smith et al. "Identification of gastrin as a growth peptide in human pancreatic cancer", Amer. J. Physiol. 268:R135-R141 (1995).					
	JF	Smith et al., "Antisense oligonucleotides to gastrin inhibit growth of human pancreatic cancer" Cancer lett. 135:107-112 (1999).					
	JG	Smith et al., "Effects of gastrin, proglumide, and somatostatin on growth of human colon cancer", Gastroenterology 95(6):1541-1548 (1988).					
	JH	Smith et al., "Elevated gastrin levels in patients with colon cancer or adenomatous polyps", Dig. Dis. Sci. 34(2):171-174 (1989).					
	JI	Smith et al., "Gastric carcinoid expresses the gastrin autocrine pathway" British Journal of Surgery, 85:1285-1289, (1998).					
	JJ	Smith et al., "Gastrin may have an autocrine/paracrine role in Barrett's oesophagus and oesophageal adenocarcinoma," British Journal of Surgery, 84:706-707, (1997).					
	JK	Sobhani et al., "Chronic endogenous hypergastrinemia in humans: Evidence for a mitogenic effect on the colonic mucosa", Gastroenterology 105(1):22-30 (1993).					
	JL	Sobhani et al., "Immunohistochemical characterization of gastrinomas with antibodies specific to different fragments of progastrin" Gastroenterol. Clin. Biol. 13:865-872 (1989).					
	JM	Soll et al., "Gastrin-receptors on isolated canine parietal cells" J. Clin. Invest. 73:1434-1447 (1984).					
	JN	Song et al., "The human gastrin/cholecystokinin type B receptor gene: alternative splice donor site in exon 4 generates two variant mRNAs" Proc. Natl. Acad. Sci. 90(19):9085-9089 (1993).					
	JO	Spitler, L.E., "Cancer Vaccines: The Interferon Analogy," Cancer Biotherapy, 10:1-3, (1995).					
	JP	Stepan et al., "Glycine-extended gastrin exerts growth-promoting effects on colon cancer cell lines" Gastroenterology 110(4):A1122 (1996).					
	JQ	Stepan et al., "Glycine-extended gastrin exerts growth-promoting effects on colon cancer cell lines" Mol. Med. 5(3):147-159 (1999).					
	JR	Sugano, et al. "Identification and characterization of glycine-extended post translational processing intermediates of progastrin in porcine stomach", J. of Biological Chemistry 260: 11724-11729 (1985).					
	JS	Takinami et al., "YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo" Ailment. Pharmacol. Ther. 11(1):113-120 (1997).					
	JT	Talley et al., "Risk for colorectal adenocarcinoma in pernicious anemia" Annals of Internal Medicine 111(9):738-742 (1989).					
	JU	Tang et al., "Expression of receptors for gut peptides in human pancreatic adenocarcinoma and tumor-free pancreas" Brit. J. Cancer 75(10):1467-1473 (1997).					
	JV	Tarasova et al., "Anti-peptide antibodies specific for the gastrin-cholecystokinin-B receptor," Letters in Peptide Science, 1:221-228, (1995).					
	JW	Tarasova et al., "Endocytosis of gastrin in cancer cells expressing gastrin/CCK-B receptor" Cell and Tissue Research, 287:325-333 (1997).					
	JX	Taylor, "Chemotherapy, radiotherapy and immunology of colorectal neoplasia" Current opinion in Gastroenterology 9:28-33 (1993).					
	JY	Thorndyke, M. and G.J. Dockray, "Identification and localization of material with gastrin-like immunoreactivity in the neutral ganglion of a photochordate, ciona intestinalis," Regulatory Peptides 16:269-279, (1986).					
Examiner Signature				Date Considered			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							


Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17118-061US1/2840US	Application No. 09/700,402
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))			Applicant Gevas et al.	
			Filing Date May 4, 2001	Group Art Unit 1643
Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner Initial	Desig. ID	Document		
	JZ	Tielemans et al., "Proliferation of enterochromaffinlike cells in omeprazole-treated hypergastrinemic rats" Gastroenterology 96(3):723-729 (1989).		
	KA	Torosian et al., "Colon carcinoma metastatic to thigh-- an unusual site of metastasis. Report of a case." Diseases of the Colon and Rectum 30(10):805-808 (1987).		
	KB	Tschmelitsch et al., "Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil)" Cancer Res. 57:2181-2186 (1997).		
	KC	Ullrich et al. "Signal transduction by receptors with tyrosine kinase activity" Cell 61:203-212 (1990).		
	KD	UniProtKB/Swiss-Prot entry P01350, (1986) (accessed on 03.26.2007).		
	KE	Upp et al., "Polyamine levels and Gastrin Receptors in Colon Cancers", Ann. Surg. 207(6):662-669 (1988).		
	KF	Vaillant et al. "Repeat liver resection for recurrent colorectal metastasis," British J. Surgery 80(3):340-344 (1993).		
	KG	Vaillant et al., "Cellular origins of different forms of gastrin: The specific immunocytochemical localization of related peptides," J. Histochem Cytochem 27:932-935 (1979).		
	KH	Varndell et al., "Intracellular topography of immunoreactive gastrin demonstrated using electron immunocytochemistry" Experientia 39:713-717 (1983).		
	KI	Varro et al., "Pathways of processing of the gastrin precursor in rat antral mucosa" J. Clin. Invest. 95:1642-1649 (1995).		
	KJ	Varro et al., "Post-translational processing of progastrin: inhibition of cleavage, phosphorylation and sulphation by brefeldin A" Biochem J. 295:813-819 (1993).		
	KK	Varro et al., "The Human Gastrin Precursor", Biochem J. 256:951-957 (1988).		
	KL	Vauthey et al., "Factors affecting long-term outcome after hepatic resection for Hepatic-cellular carcinoma," Am. J. Surgery 169: 28-35 (1995).		
	KM	Wang et al., "Processing and proliferative effects of human progastrin in transgenic mice" J. Clin. Invest. 98(8):1918-1929 (1996).		
	KN	Wank "Cholecystokinin receptors (editorial)" Am. J. Physiol. 269:G628-G646 (1995).		
	KO	Wank et al., "Brain and gastrointestinal cholecystokinin receptor family: structure and functional expression" Proc. Nat. Acad. Sci. 89:8691-8695 (1992).		
	KP	Wank et al., "Cholecystokinin receptor family. Molecular Cloning, structure, and functional expression in rat, guinea pig, and human" Ann. N.Y. Acad. Sci. 713:49-66 (1994).		
	KQ	Watson et al., "A comparison of an anti-gastrin antibody and cytotoxic drugs in the therapy of human gastric ascites in SCID mice," International Journal of Cancer, 81(2):248-254, (1999).		
	KR	Watson et al., "Anti-gastrin antibodies raised by gastrimmune inhibit growth of colorectal tumor AP5" Int. J. Cancer, 61(2):233-240 (1995).		
	KS	Watson et al., "Detection of gastrin receptors on gastrointestinal tumors using the anti-gastrin receptor monoclonal antibody, 2CL" Gut 4: F271 (1993).		
	KT	Watson et al., "Expression of gastrin-CCKB receptor isoforms in gastrointestinal tumor cells" Int. J. Cancer 77(4):572-577 (1998).		

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17118-061US1/2840US	Application No. 09/700,402
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))				Applicant Gevas et al.	
				Filing Date May 4, 2001	Group Art Unit 1643
Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner Initial	Desig. ID	Document			
	KU	Watson et al., "Expression of gastrin-CCKB receptor isoforms in gastrointestinal tumor cells: Relationship to gastrin secretion," Proceedings of the American Association for Cancer Research Annual Meeting, 38(0):116 (Abstract 773), (1997).			
	KV	Watson et al., "Gastrin antagonists and gastrointestinal tumors," Expert Opinion on Investigational Drugs, 4(12):1253-1266, (1995).			
	KW	Watson et al., "Gastrin antagonists in the treatment of gastric cancer" Anticancer Drugs 4(6):599-604 (1993).			
	KX	Watson et al., "Gastrin Receptors in Gastrointestinal Tumors", Medical Intelligence Unit, R.G. Landes Company, Georgetown, TX. pp1-99, (1993).			
	KY	Watson et al., "Inhibition of gastrin-stimulated growth of gastrointestinal tumour cells by octreotide and the gastrin/cholecystokinin receptor antagonists, proglumide and lorglumide," European Journal of Cancer, 28A(8-9):1462-1467, (1992).			
	KZ	Watson et al., "Inhibitory effects of the gastrin receptor antagonist (L-365,260) on gastrointestinal tumor cells," Cancer, 68:1255-1260, (1991).			
	LA	Watson et al., "Pre-clinical evaluation of the Gastrimmune immunogen alone and in combination with 5-fluorouracil/leucovorin in a rat colorectal cancer model" Int. J. Cancer 75(6):873-877 (1998).			
	LB	Watson et al., "The effect of the E2 prostaglandin enprostil, and the somatostatin analogue sms201995, on the growth of a human gastric cell line, MKN45G" Int. J. Cancer 45:90-94 (1990).			
	LC	Watson et al., "The in vitro growth response of primary human colorectal and gastric cancer cells to gastrin," International Journal of Cancer, 43:692-696, (1989).			
	LD	Watson et al., "Therapeutic effect of the gastrin receptor antagonist, CR2093 on gastrointestinal tumour cell growth," British Journal of Cancer, 65(6):879-883, (1992).			
	LE	Watson et al., "Antibodies targeting the amino terminal portion of the human CCKB/gastrin receptor inhibit the liver invasion of a human colonic tumor," Gastroenterology 114(4 Part 2): A701 (Abstract # G2899) (April 15, 1998).			
	LF	Watson et al., "Antibodies targeting the Amino Terminal portion of the Human CCKB/gastrin receptor inhibit the liver invasion of a human colonic tumour," Research Presentation, Digestive Disease Week, American Gastroenterological Association (1998), 17 slides.			
	LG	Watson et al., "Effect of gastrin neutralization on the progression of the adenoma:carcinoma sequence in the Min mouse model of familial adenomatous polyposis," Gastroenterology 114(Supplement 1): A701 (Abstract #G2900) (April 15, 1998).			
	LH	Watson, S.A., et al., "Gastrin: growth enhancing effects on human gastric and colonic tumour cells," British Journal of Surgery, 75(4):342-345, (1988).			
	LI	Weinberg et al., "Cholecystokinin A and B receptors are differentially expressed in normal pancreas and pancreatic adenocarcinoma" J. Clin. Invest. 100(3):597-603 (1997).			
	LJ	Weinstock et al., "Binding of gastrin(17) to human gastric carcinoma cell lines" Cancer Res. 48(4):932-937 (1988).			
	LK	Wendlberger et al., "The syntheses of human big gastrin I and its 32-leucine analog", Chemical Abstracts 92(21):722 [Abstract #92:198749s] (1980).			
	LL	Wong et al., "Postprandial hypergastrinaemia in patients with colorectal cancer" Gut 32:1352-1354 (1991).			
	LM	Wunsch et al., "Biological and immunological properties of human gastrin I analogues" Hoppe-Syler's Z. Physiol. Chem. 363:665-669 (1982).			
Examiner Signature			Date Considered		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17118-061US1/2840US	Application No. 09/700,402
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))				Applicant Gevas et al.	
				Filing Date May 4, 2001	Group Art Unit 1643
Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner Initial	Desig. ID	Document			
	LN	Yamaguchi et al., "Amino-terminal immunoreactivity of big gastrin in plasma and tumors obtained from patients with Zollinger-Ellison Syndrome" Chem. Abstracts 100:373 (1984) [Abstract #100:154661m].			
	LO	Yanaihara et al. "A new type of gastrin derivative and its use for production of central region-specific anti-gastrin sera" Biomedical Research 1:242-247 (1980).			
	LP	Yanaihara et al. "Human Big Gastrin N-terminal Fragment Immunoreactivity" In: Gut Peptides, Elsevier, North-Holland Biomed. Press, pages 26-33, (1979).			
	LQ	Zhou et al., "Cholecystokinin B Receptor, Gastrin Receptor, CCK2 receptor [Homo sapiens] (1992-2004)-NCBI Protein Sequence Accession No. NP_795344			

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Gevas *et al.*
Serial No. : 09/700,402
Filed : May 4, 2001

Art Unit : 1643
Examiner : Sheela J. Huff
Cust. No. : 20985
Conf. No. : 3611

Title : COMBINATION THERAPY FOR THE TREATMENT OF TUMORS

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL


Dear Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement (7 pages), Form PTO-1449 (15 pages), cited non U.S. patent documents listed on the form PTO-1449, documents listed in table of Supplementary Information Disclosure Statement (50 documents, including International Preliminary Examination Report, two European Examination Reports, Australian Examination Report, Chinese Examination Report with English translation, Canadian Office Action, and four U.S. Office Actions), a check in the amount of \$180.00, and a return postcard for filing in connection with the above-captioned application.



The Commissioner is hereby authorized to charge the fee for the extension of time and any other fee that may be due in connection with this and the attached papers or with this application during its entire pendency to Deposit Account No. 06-1050. A duplicate of this sheet is enclosed.

Respectfully submitted,


Stephanie Seidman
Reg. No. 33,779

Attorney's Docket No.: 17118-061US1/2840US
Address all correspondence to:
Stephanie Seidman
Fish & Richardson P.C.
12390 El Camino Real
San Diego, California 92130
Telephone: (858) 678-4777
Facsimile: (202) 626-7796
email: seidman@fr.com

CERTIFICATE OF MAILING BY "EXPRESS MAIL"
"Express Mail" Mailing Label Number EV 965982585 US
Date of Deposit September 27, 2007
I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.


Stephanie Seidman